Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes

Science Translational Medicine

Volumn 7, Issue 319, 2015, Pages

  Burak, M Furkan ^a,e   Inouye, Karen E ^a   White, Ariel ^a   Lee, Alexandra ^a   Tuncman, Gurol ^a   Calay, Ediz S ^a   Sekiya, Motohiro ^a   Tirosh, Amir ^a   Eguchi, Kosei ^a   Birrane, Gabriel ^b   Lightwood, Daniel ^c   Howells, Louise ^c   Odede, Geofrey ^c   Hailu, Hanna ^c   West, Shauna ^c   Garlish, Rachel ^c   Neale, Helen ^c   Doyle, Carl ^c   Moore, Adrian ^c   Hotamisligil, Gökhan S ^a,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UCB (Union Chimique Belge)   (United Kingdom)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e MOUNT AUBURN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EPITOPE; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN AP2; GLUCOSE; INSULIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CA33; UNCLASSIFIED DRUG; FABP4 PROTEIN, HUMAN; FABP4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DIET RESTRICTION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; FAT MASS; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; IN VIVO STUDY; INSULIN SENSITIVITY; MALE; METABOLIC REGULATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN STRUCTURE; ADIPOSE TISSUE; AMINO ACID SEQUENCE; ANIMAL; BODY COMPOSITION; C57BL MOUSE; CHEMISTRY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LIPID DIET; METABOLISM; METABOLOME; MOUSE MUTANT; PATHOLOGY;

ADIPOSE TISSUE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BODY COMPOSITION; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; FATTY ACID-BINDING PROTEINS; FATTY LIVER; GLUCOSE; HUMANS; INSULIN; MALE; METABOLOME; MICE, INBRED C57BL; MICE, OBESE;

EID: 84954459329     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac6336     Document Type: Article

References (60)

1. G. S. Hotamisligil, Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
2. E. D. Rosen, B. M. Spiegelman, Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444, 847-853 (2006).
3. H. Waki, P. Tontonoz, Endocrine functions of adipose tissue. Annu. Rev. Pathol. 2, 31-56 (2007).
4. A. V. Hertzel, D. A. Bernlohr, The mammalian fatty acid-binding protein multigene family: Molecular and genetic insights into function. Trends Endocrinol. Metab. 11, 175-180 (2000).
5. M. Furuhashi, G. S. Hotamisligil, Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov. 7, 489-503 (2008).
6. G. S. Hotamisligil, D. A. Bernlohr, Metabolic functions of FABPs - Mechanisms and therapeutic implications. Nat. Rev. Endocrinol. 11, 592-605 (2015).
7. H. Cao, K. Gerhold, J. R. Mayers, M. M. Wiest, S. M. Watkins, G. S. Hotamisligil, Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 134, 933-944 (2008).
8. G. S. Hotamisligil, R. S. Johnson, R. J. Distel, R. Ellis, V. E. Papaioannou, B. M. Spiegelman, Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274, 1377-1379 (1996).
9. K. Maeda, H. Cao, K. Kono, C. Z. Gorgun, M. Furuhashi, K. T. Uysal, Q. Cao, G. Atsumi, H. Malone, B. Krishnan, Y. Minokoshi, B. B. Kahn, R. A. Parker, G. S. Hotamisligil, Adipocyte/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab. 1, 107-119 (2005).
10. M. Furuhashi, R. Fucho, C. Z. Görgün, G. Tuncman, H. Cao, G. S. Hotamisligil, Adipocyte/ macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J. Clin. Invest. 118, 2640-2650 (2008).
11. L. Makowski, J. B. Boord, K. Maeda, V. R. Babaev, K. T. Uysal, M. A. Morgan, R. A. Parker, J. Suttles, S. Fazio, G. S. Hotamisligil, M. F. Linton, Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 7, 699-705 (2001).
12. M. Furuhashi, G. Tuncman, C. Z. Görgün, L. Makowski, G. Atsumi, E. Vaillancourt, K. Kono, V. R. Babaev, S. Fazio, M. F. Linton, R. Sulsky, J. A. Robl, R. A. Parker, G. S. Hotamisligil, Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447, 959-965 (2007).
13. M. D. Layne, A. Patel, Y.-H. Chen, V. I. Rebel, I. M. Carvajal, A. Pellacani, B. Ith, D. Zhao, B. M. Schreiber, S.-F. Yet, M.-E. Lee, J. Storch, M. A. Perrella, Role of macrophage-expressed adipocyte fatty acid binding protein in the development of accelerated atherosclerosis in hypercholesterolemic mice. FASEB J. 15, 2733-2735 (2001).
14. J. B. Boord, K. Maeda, L. Makowski, V. R. Babaev, S. Fazio, M. F. Linton, G. S. Hotamisligil, Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 22, 1686-1691 (2002).
15. H. Cao, M. Sekiya, M. E. Ertunc, M. F. Burak, J. R. Mayers, A. White, K. Inouye, L. M. Rickey, B. C. Ercal, M. Furuhashi, G. Tuncman, G. S. Hotamisligil, Adipocyte lipid chaperone aP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab. 17, 768-778 (2013).
16. M. E. Ertunc, J. Sikkeland, F. Fenaroli, G. Griffiths, M. P. Daniels, H. Cao, F. Saatcioglu, G. S. Hotamisligil, Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity. J. Lipid Res. 56, 423-434 (2015).
17. T. Mita, M. Furuhashi, S. Hiramitsu, J. Ishii, K. Hoshina, S. Ishimura, T. Fuseya, Y. Watanabe, M. Tanaka, K. Ohno, H. Akasaka, H. Ohnishi, H. Yoshida, S. Saitoh, K. Shimamoto, T. Miura, FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKGdependent lipolytic mechanisms. Obesity 23, 359-367 (2015).
18. I. Schlottmann, M. Ehrhart-Bornstein, M. Wabitsch, S. R. Bornstein, V. Lamounier-Zepter, Calcium-dependent release of adipocyte fatty acid binding protein from human adipocytes. Int. J. Obes. 38, 1221-1227 (2014).
19. S. Kralisch, T. Ebert, U. Lossner, B. Jessnitzer, M. Stumvoll, M. Fasshauer, Adipocyte fatty acid-binding protein is released from adipocytes by a non-conventional mechanism. Int. J. Obes. 38, 1251-1254 (2014).
20. S. Kralisch, N. Klöting, T. Ebert, M. Kern, A. Hoffmann, K. Krause, B. Jessnitzer, U. Lossner, I. Sommerer, M. Stumvoll, M. Fasshauer, Circulating adipocyte fatty acid-binding protein induces insulin resistance in mice in vivo. Obesity 23, 1007-1013 (2015).
21. A. Xu, Y. Wang, J. Y. Xu, D. Stejskal, S. Tam, J. Zhang, N. M. S. Wat, W. K. Wong, K. S. L. Lam, Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin. Chem. 52, 405-413 (2006).
22. H. J. Yoo, S. Kim, M. S. Park, H. Y. Choi, S. J. Yang, J. A. Seo, S. G. Kim, N. H. Kim, S. H. Baik, D. S. Choi, K. M. Choi, Serum adipocyte fatty acid-binding protein is associated independently with vascular inflammation: Analysis with 18F-fluorodeoxyglucose positron emission tomography. J. Clin. Endocrinol. Metab. 96, E488-E492 (2011).
23. M. von Eynatten, L. P. Breitling, M. Roos, M. Baumann, D. Rothenbacher, H. Brenner, Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: A 10-year prospective study. Arterioscler. Thromb. Vasc. Biol. 32, 2327-2335 (2012).
24. J.-B. Suh, S. M. Kim, G.-J. Cho, K. M. Choi, Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease. Scand. J. Gastroenterol. 49, 979-985 (2014).
25. M. Furuhashi, S. Ishimura, H. Ota, M. Hayashi, T. Nishitani, M. Tanaka, H. Yoshida, K. Shimamoto, G. S. Hotamisligil, T. Miura, Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLOS One 6, e27356 (2011).
26. S. Ishimura, M. Furuhashi, Y. Watanabe, K. Hoshina, T. Fuseya, T. Mita, Y. Okazaki, M. Koyama, M. Tanaka, H. Akasaka, H. Ohnishi, H. Yoshida, S. Saitoh, T. Miura, Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLOS One 8, e81318 (2013).
27. S. E. Karakas, R. U. Almario, K. Kim, Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers. Metabolism 58, 1002-1007 (2009).
28. B. M. Kaess, D. M. Enserro, D. D. McManus, V. Xanthakis, M.-H. Chen, L. M. Sullivan, C. Ingram, C. J. O'Donnell, J. F. Keaney, R. S. Vasan, N. L. Glazer, Cardiometabolic correlates and heritability of fetuin-A, retinol-binding protein 4, and fatty-acid binding protein 4 in the Framingham Heart Study. J. Clin. Endocrinol. Metab. 97, E1943-E1947 (2012).
29. A. Cabré, I. Lázaro, J. Girona, J. M. Manzanares, F. Marimón, N. Plana, M. Heras, L. Masana, Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 195, e150-e158 (2007).
30. M. M. Balci, U. Arslan, H. Firat, I. Kocaoglu, M. G. Vural, K. G. Balci, O. Maden, O. A. Gürbüz, S. Ardiç, E. Yeter, Serum levels of adipocyte fatty acid-binding protein are independently associated with left ventricular mass and myocardial performance index in obstructive sleep apnea syndrome. J. Invest. Med. 60, 1020-1026 (2012).
31. W. S. Chow, A. W. K. Tso, A. Xu, M. M. A. Yuen, C. H. Y. Fong, T. H. Lam, S. V. Lo, H. F. Tse, Y. C. Woo, C. Y. Yeung, B. M. Y. Cheung, K. S. L. Lam, Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a communitybased cohort: A 12-year prospective study. J. Am. Heart Assoc. 2, e004176 (2013).
32. C.-L. Huang, Y.-W. Wu, C.-C. Wu, L. Lin, Y.-C. Wu, P.-Y. Hsu, Y.-S. Jong, W.-S. Yang, Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. Cardiovasc. Diabetol. 12, 105 (2013).
33. G. Tuncman, E. Erbay, X. Hom, I. De Vivo, H. Campos, E. B. Rimm, G. S. Hotamisligil, A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl. Acad. Sci. U.S.A. 103, 6970-6975 (2006).
34. J. Saksi, P. Ijäs, M. I. Mäyränpää, K. Nuotio, P. M. Isoviita, J. Tuimala, E. Lehtonen-Smeds, M. Kaste, A. Jula, J. Sinisalo, M. S. Nieminen, M.-L. Lokki, M. Perola, A. S. Havulinna, V. Salomaa, J. Kettunen, M. Jauhiainen, P. T. Kovanen, P. J. Lindsberg, Low-expression variant of fatty acid-binding protein 4 favors reduced manifestations of atherosclerotic disease and increased plaque stability. Circ. Cardiovasc. Genet. 7, 588-598 (2014).
35. J. M. Olefsky, J. J. Nolan, Insulin resistance and non-insulin-dependent diabetes mellitus: Cellular and molecular mechanisms. Am. J. Clin. Nutr. 61, 980S-986S (1995).
36. R. E. Gillilan, S. D. Ayers, N. Noy, Structural basis for activation of fatty acid-binding protein 4. J. Mol. Biol. 372, 1246-1260 (2007).
37. A. E. Jenkins, J. A. Hockenberry, T. Nguyen, D. A. Bernlohr, Testing of the portal hypothesis: Analysis of a V32G, F57G, K58G mutant of the fatty acid binding protein of the murine adipocyte. Biochemistry 41, 2022-2027 (2002).
38. L. Scheja, L. Makowski, K. T. Uysal, S. M. Wiesbrock, D. R. Shimshek, D. S. Meyers, M. Morgan, R. A. Parker, G. S. Hotamisligil, Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 48, 1987-1994 (1999).
39. A. V. Hertzel, L. A. Smith, A. H. Berg, G. W. Cline, G. I. Shulman, P. E. Scherer, D. A. Bernlohr, Lipid metabolism and adipokine levels in fatty acid-binding protein null and transgenic mice. Am. J. Physiol. Endocrinol. Metab. 290, E814-E823 (2006).
40. N. R. Coe, M. A. Simpson, D. A. Bernlohr, Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J. Lipid Res. 40, 967-972 (1999).
41. M. R. A. A. Syamsunarno, T. Iso, A. Yamaguchi, H. Hanaoka, M. Putri, M. Obokata, H. Sunaga, N. Koitabashi, H. Matsui, K. Maeda, K. Endo, Y. Tsushima, T. Yokoyama, M. Kurabayashi, Fatty acid binding protein 4 and 5 play a crucial role in thermogenesis under the conditions of fasting and cold stress. PLOS One 9, e90825 (2014).
42. D. A. Bernlohr, N. R. Coe, M. A. Simpson, A. V. Hertzel, Regulation of gene expression in adipose cells by polyunsaturated fatty acids. Adv. Exp. Med. Biol. 422, 145-156 (1997).
43. K. Maeda, K. T. Uysal, L. Makowski, C. Z. Görgün, G. Atsumi, R. A. Parker, J. Brüning, A. V. Hertzel, D. A. Bernlohr, G. S. Hotamisligil, Role of the fatty acid binding protein mal1 in obesity and insulin resistance. Diabetes 52, 300-307 (2003).
44. Y.-W. Won, P. P. Adhikary, K. S. Lim, H. J. Kim, J. K. Kim, Y.-H. Kim, Oligopeptide complex for targeted non-viral gene delivery to adipocytes. Nat. Mater. 13, 1157-1164 (2014).
45. R. H. Unger, A. D. Cherrington, Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J. Clin. Invest. 122, 4-12 (2012).
46. G. F. Cahill Jr., Fuel metabolism in starvation. Annu. Rev. Nutr. 26, 1-22 (2006).
47. H. Y. Cai, T. Wang, J. C. Zhao, P. Sun, G. R. Yan, H. P. Ding, Y. X. Li, H. Y. Wang, W. L. Zhu, K. X. Chen, Benzbromarone, an old uricosuric drug, inhibits human fatty acid binding protein 4 in vitro and lowers the blood glucose level in db/db mice. Acta Pharmacol. Sin. 34, 1397-1402 (2013).
48. R. L. C. Hoo, I. P. C. Lee, M. Zhou, J. Y. L. Wong, X. Hui, A. Xu, K. S. L. Lam, Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice. J. Hepatol. 58, 358-364 (2013).
49. H. Lan, C. C. Cheng, T. J. Kowalski, L. Pang, L. Shan, C.-C. Chuang, J. Jackson, A. Rojas-Triana, L. Bober, L. Liu, J. Voigt, P. Orth, X. Yang, G. W. Shipps Jr., J. A. Hedrick, Small-molecule inhibitors of FABP4/5 ameliorate dyslipidemia but not insulin resistance in mice with dietinduced obesity. J. Lipid Res. 52, 646-656 (2011).
50. X. Miao, Y. Wang, W. Wang, X. Lv, M. Wang, H. Yin, The mAb against adipocyte fatty acid-binding protein 2E4 attenuates the inflammation in the mouse model of high-fat diet-induced obesity via toll-like receptor 4 pathway. Mol. Cell. Endocrinol. 403, 1-9 (2015).
51. R. H. Zubler, F. Erard, R. K. Lees, M. Van Laer, C. Mingari, L. Moretta, H. R. MacDonald, Mutant EL-4 thymoma cells polyclonally activate murine and human B cells via direct cell interaction. J. Immunol. 134, 3662-3668 (1985).
52. A. M. Clargo, A. R. Hudson, W. Ndlovu, R. J. Wootton, L. A. Cremin, V. L. O'Dowd, C. R. Nowosad, D. O. Starkie, S. P. Shaw, J. E. Compson, D. P. White, B. MacKenzie, J. R. Snowden, L. E. Newnham, M. Wright, P. E. Stephens, M. R. Griffiths, A. D. G. Lawson, D. J. Lightwood, The rapid generation of recombinant functional monoclonal antibodies from individual, antigen-specific bone marrowderived plasma cells isolated using a novel fluorescence-based method. mAbs 6, 143-159 (2014).
53. J. F. Kearney, A. Radbruch, B. Liesegang, K. Rajewsky, A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J. Immunol. 123, 1548-1550 (1979).
54. G. Köhler, C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
55. A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, R. J. Read, Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
56. A. T. Brunger, Version 1.2 of the Crystallography andNMR system. Nat. Protoc. 2, 2728-2733 (2007).
57. P. Emsley, K. Cowtan, Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
58. C. D. Kane, D. A. Bernlohr, A simple assay for intracellular lipid-binding proteins using displacement of 1-anilinonaphthalene 8-sulfonic acid. Anal. Biochem. 233, 197-204 (1996).
59. E. G. Bligh, W. J. Dyer, A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-917 (1959).
60. I. Petrescu, O. Bojan, M. Saied, O. Bârzu, F. Schmidt, H. F. Kühnle, Determination of phosphoenolpyruvate carboxykinase activity with deoxyguanosine 5′-diphosphate as nucleotide substrate. Anal. Biochem. 96, 279-281 (1979).